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ackground: Atrial fibrillation (AF) is the common cardiac arrhythmia in which heart beats 
irregularly usually greater than 100 beats per minutes. AF is well-documented public health 
problem causing substantial mortality and morbidity. Metabolic syndrome (MS) is a collection of 
metabolic risk factors like diabetes, hypertension, dyslipidemia, obesity and impaired glucose level 
that exists in one person. The aim of the present study is to find the relation between AF and MS.  
Methods: 100 patients of AF were sampled from Punjab Institute of Cardiology, Lahore from December, 
2014 to June 2015. These patients were divided into two AF groups, 50 without MS and 50 with MS. 25 
healthy subjects were also included for the comparison. Lipid profile was assessed by chemistry analyzer 
and serum insulin was measured by ELISA.  
Results: In our population, there was significantly high levels of insulin resistance (IR) and obesity in AF 
groups (without MS and with MS) as compared with healthy subjects (P<0.05). Highly significant 
differences was observed in relation with other parameters e.g. hypertension, hypertriglyceridemia, HDL-
C among the studied groups (P<0.05). Significant positive correlation was observed between insulin and 
lipid profile (TC, TG, LDL) while inverse with HDL.  
Conclusion: The indictors of metabolic syndrome were significantly correlated with AF in the studied 
subjects, while IR was found significantly higher in MS group.  
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Introduction  
Atrial fibrillation or AF is usually cardiac arrhythmia in 
which heart beats irregularly usually too fast. AF affects 
33.5 million people at global level [1]. After 80 years of 
age 8% of the individuals are affected with AF so age is a 
major risk for the development of AF. “It took 69 years 
for the percentage to double from 7% to 14% in the 
United States (1944 to 2013), but this doubling of the 
over 65 age group is expected to occur in only 26 years 
in China (2000 to 2026). The burden of AF at age 65 
years (226 DALYs/100,000) is nearly 7 times that at age 
45 years (33 DALYs/100,000) and only one-quarter that 
at ages 80 and older (936 DALYs/100,000)” [1]. 
The causes of AF are aging, cardiomyopathy, valvular 
heart diseases, coronary artery disease, obesity, diabetes 
mellitus, chronic obstructive pulmonary diseases, 
structural heart diseases, hypertension, excessive alcohol 
consumption, sleep disturbances, thyroid dysfunction, 
chronic renal diseases, congenital heart diseases and 
previous heart surgery. Some of the genetic mutations 
may be responsible for the development of AF [2]. The 
signs and symptoms of AF are rapid heart rate, shortness 
of breath, swelling, palpitation, fatigue, discomfort, 
dizziness, weakness, and exercise intolerance all these 
symptoms lead to fainting or collapse [3, 4]. 
Metabolic syndrome is referred to a condition in 
which energy storage and utilization are present. It is 
defined as cluster of metabolic risk factors. The 
clustering category of metabolic syndrome is known as 
a syndrome X. The prevalence of metabolic syndrome 
increases as age increased and in USA about 34% adult 
populations have Metabolic Syndrome [5, 6]. Metabolic 
syndrome is a premier risk factor for cardiovascular 
disease. It is also a risk factor for the development AF, it 
increases the mortality rate about 1.5 fold and 2-fold 
increases the cardiovascular events [7].  
The linking factors that develops the relationship of 
AF with metabolic syndrome are oxidative stress, 
inflammation, insulin resistance, high plasma volume, 
neurohormonal activation, atrial remodeling which  
changes the ion channel, atrial structure, cellular 
hypertrophy, tissue fibrosis, activation of fibroblasts, 
calcium homeostasis, sympathetic activity increase,  left 
ventricular diastolic activity is also increased, loss of 
muscle mass, mechanical stress, atrium enlargement, 
spatial remodeling of gap junction, fibrosis and  
increases  the conduction system of heart activity [8]. 
Insulin is secreted from beta cells of pancreas. The 
decreased sensitivity of target tissues of insulin secretion 
is called insulin resistances. It is also called type 2 
diabetes mellitus which is non- insulin dependent 
diabetes mellitus (NIDDM), is caused by decreased 
sensitivity to insulin. It is primary cause of increased 
blood glucose concentration. It is also the major cause of 
cardiovascular diseases [9, 10].   
Methods 
Study design 
This cross-sectional study (n=125) was conducted in 
Punjab Institute of Cardiology, Lahore from December, 
2014 to June 2015.  Sample size was calculated by 
Raosoft software using 7% margin of error, with 
response distribution of 65%. The subjects were selected 
from outdoor patients and from Emergency 
Department of Jilani block. The subjects suffering from 
atrial fibrillation were diagnosed by the expert 
physicians of PIC on the basis of ECG and they were not 
suffering from any other disorder. A total of 100 subjects 
suffering from AF were selected that were further 
categorized into two groups on the presence and 
absence of metabolic syndrome. AF group without MS 
(n=50) and AF group with MS (n=50). Normal healthy 
subjects (n=25) of same age group were also included for 
comparison. 
Estimation of BMI and WHR 
BMI was calculated by weight in kg and height in meters 
square by using the formula as Weight (kg) /Height (m)2 
[11]. For the measurement of WHR or waist hip ratio, a 
tape measuring was used to measure circumference of 
his or her 1 inch (2.54 cm) above the umbilicus and hips.   
Estimation of systolic and diastolic blood pressure 
Both the systolic and diastolic blood pressure was 
measured by using the B.P apparatus/ 
sphygmomanometer. 
Estimation of FBG, TC, triglycerides levels, LDL-C 
and HDL-C parameters 
Fasting Blood Glucose (FBG) were measured by using 
the glucometer. Serum was used for the measurement of 
total cholesterol, triglycerides levels, LDL-C and HDL-C 
by using the kits on chemical analyzer. 
Estimation of insulin and insulin resistance (IR) 
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The NCEP-ATP III report (2001) defined the criteria of 
MS [12]. The insulin levels were measured by Enzyme-
Linked Immunosorbent Assay (ELISA). Insulin 
resistance was measured by using the formula. = 
(Fasting plasma insulin [micro units per milliliter]) x 
(Fasting plasma glucose [micromole per liter]) / 22.5 
[13]. 
Statistical analysis 
The datasheet was made on MS excel 2015. Data was 
expressed as mean ± SEM. Difference between the 
groups was determined with the help of one way 
ANOVA test. While all the statements of significance 
were based on the probability level of 0.05 and highly 
significant were based on 0.01 level of probability at 95% 
confidences interval. The relationship between the 
parameters was found out by bivariate Pearson 
correlation analysis. The analysis was done with the help 
of SPSS version 20. 
Results 
This study was done on 125 subjects that were divided 
into three groups, control group (n=25), AF group 
without MS (n=50) and with MS (n=50). The subjects 
were further categorized on the basis of gender. In 
control group, 50% (n = 12) were males while 50% (n = 
13) subjects were females. In AF groups both without 
and with MS. 42% (n = 21) subjects were males and 58% 
(n = 29) subjects were females. 
The demographic and biochemical characteristics of 
the study population were presented in table 1.  The 
subjects with and without metabolic syndrome have 
higher insulin levels and insulin resistance as compared 
to the control group. ANOVA revealed significant 
differences in the BMI, WHR, systolic, diastolic blood 
pressure and lipid profile in the atrial fibrillated subjects 
as compared to control (p<0.05). While IR was 
significantly higher in males of with and without 
metabolic syndrome groups.  
The relationship of insulin with biochemical 
parameters was also found out by using two-tailed 
Pearson correlation analysis presented in table 2. 
The relationship of insulin and insulin resistance with 
lipid profile was significantly correlated in AF group 
with and without MS. 
 
 
Variables Control 
group 
(n=25) 
AF group 
without MS   
(n=50) 
AF group 
with MS  
(n=50) 
P value  
Age (years) 47.00 ±1.32 49.13 ±1.94 48.12±2.50 0.834 
Height (cm) 1.60 ±0.01  1.58±0.00 1.63±0.02 0.074 
Weight (kg)  59.88±1.79 57.48±1.40 72.30±1.91 0.000** 
BMI (kg/m2) 23.40±0.43 22.93±0.53 29.41±1.03 0.000** 
WHR 0.816±0.01 0.80±0.00 0.94±0.00 0.000** 
Systolic B.P 112.4±1.66 115.92±2.17 134.00±3.62 0.000** 
Diastolic B.P 85.60 ±1.16 74.71±1.40 86.40±2.05 0.000** 
FBG (mg/dl) 91.16±4.03 101.56±3.58 178.52±16.22 0.000** 
TC (mg/dl) 179.62 ±3.87 168.52±18.78 191.41±8.57 0.470 
TG (mg/dl) 83.14±13.12 134.38±4.40 154.38±7.75 0.000** 
HDL-
C(mg/dl) 
40.00±1.56 11.72±0.26 12.71±0.65 0.000** 
LDL-C 
(mg/dl)  
169. 38±8.62 165.05±18.79 197.96±10.60 0.218 
Insulin(µlU/
ml) 
 13.02±4.03 25.55±5.28 22.28±3.47 0.250 
IR 1.49±0.17 8.32±1.76 10.09±1.97 0.029* 
 
 
Variables R value of insulin 
Control 
group 
AF group 
without MS 
AF group with 
MS 
FGB (mg/dl) 0.929** 0.788** 0.689** 
TC (mg/dl) 0.977** 0.518** 0.879** 
TG (mg/dl) 0.556** 0.140 0.844** 
HDL-C (mg/dl) 0.755** -0.417** -0.263** 
LDL-C(mg/dl) 0.912** 0.508** 0.847** 
Insulin (µlU/ml) --------- -------- -------- 
 
Variables R value of insulin resistance 
Control 
group 
AF group 
Without MS 
AF group 
with MS 
FGB (mg/dl) 0.959** 0.846** 0.721** 
TC (mg/dl) 0.986** 0.564** 0.901** 
TG (mg/dl) 0.628** 0.423** 0.877** 
HDL-C (mg/dl) 0.954** 0.308** 0.126 
LDL-C(mg/dl) 0.930** 0.555** 0.869** 
Insulin (µlU/ml) 0.467** 0.422** 0.295** 
 
 
 
Discussion  
Atrial fibrillation is a serious public health disease. It is 
associated with increased systemic thromboembolism, 
heart failure, and death. In the present study, age is a 
major risk factor for the prevalence of both the atrial 
fibrillation and metabolic syndrome. The study group 
was age matched. Other studies reported that at the age 
of 40-50 years, the prevalence of AF was ˂ 0.5%. The 
Table 1: Demographic and biochemical parameters of control group and AF 
groups with MS and without MS. 
Table 2: Correlation analysis of insulin and insulin resistance with 
biochemical parameters in control group and AF group without MS and 
with MS. 
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individuals with the age of 80 years, it was 5-15%. The 
individual that aged ≥85 years; it was 18%. In the past 
two decades the incidence of AF had increased about 
13%. It was affecting more males as compared to females 
[14, 15] as compared to this study where 58% subjects 
were females.  
In the present study the BMI and WHR, both are 
significantly higher in AF group as compared to control. 
While in the AF group with MS, females were 
overweight as compared to control females. These 
results were similar to other studies which indicated that 
obesity was a major risk factor for the atrial fibrillation. 
Increased BMI also predispose individuals to other 
disease like hypertension and diabetes [16, 17]. In our 
general population it ultimately increases the health 
risks. 
In present study, blood insulin levels have been raised 
in AF group as compared to control but contradictory 
results have been reported in the Framingham cohort 
study between insulin resistance and AF. On the 
contrary, several studies had shown that in metabolic 
syndrome, insulin resistance is a crucial component and 
is related to incidence of AF. Insulin causes 
vasoconstriction and subsequent blood pressure 
elevation [18]. In the studied group AF group without 
MS, the raised insulin levels may affect vascular 
compliance and predispose subjects to AF. 
Insulin resistance is a major component of metabolic 
syndrome and also a risk factor for cardiovascular 
diseases. Significant difference in IR was observed in the 
studied groups. It has been reported that the early onset 
of type 2 diabetes is the result of IR and then 
hypertension which also leads to various complications 
of cardiovascular diseases [19]. 
Fontes et al. reported that IR was not associated with 
AF [20]. While our study indicated that IR has a role in 
causing AF because in group without MS the IR may be 
the factor contributing towards AF. While it has been 
reported by Yuji et al. that there was increased evidence 
of link between MS and the development of AF although 
the independent effect of MS on LA size was still 
undetermined. Their study indicated that LA size was 
influenced by IR and obesity that were integral 
components of the MS. It was independently associated 
with LV hypertrophy, LV geometry and LV diastolic 
function in non-diabetic Japanese hypertensive patients 
[20]. Yuji et al. study showed that IR was highly 
prevalent among non-diabetic patients with 
hypertrophic cardiomyopathy (HCM) [21]. They also 
reported a possible mechanism by which IR was affected 
the development of AF that was mediated through its 
association with increased LA size or impaired LV 
diastolic function. IR might be an important underlying 
mechanism for the genesis of AF in HCM [22]. 
In present study significant direct association was 
observed with insulin/IR and lipid profile that revealed 
that as IR increased, the TC, TG also increased because 
of inability of insulin to perform its function.    
Insulin resistance syndrome was clinically defined as 
the presence of high blood pressure, fasting blood sugar 
≥100 mg/dL, large waist circumference, and low HDL 
and high triglycerides. These factors were also risk factor 
for AF. Insulin resistance was associated with 
inflammation, diabetes and obesity. Both diabetes and 
obesity are associated with insulin resistance. So insulin 
resistance is an intermediate step for the development of 
AF and is a common metabolic substrate that is 
associated with several cardiovascular conditions. IR is 
correlated with known AF risk factors like hypertension, 
BMI and fasting impaired glucose.  
The indictors of metabolic syndrome were 
significantly correlated with AF in the studied subjects, 
while IR was found significantly higher in MS group.  
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